|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Iteos Therapeutics, Inc. (ITOS) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
37,960,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile iTeos Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of a differentiated immuno-oncology therapeutics for patients. Co.'s product candidate, inupadenant, is designed as a selective small molecule antagonist of the adenosine A2a receptor, in the adenosine pathway, a main driver of immunosuppression in the tumor microenvironment across a range of tumors. Co.'s main antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains, an immune checkpoint with multiple mechanisms of action leading to immunosuppression.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
5,000 |
5,000 |
Total Buy Value |
$0 |
$0 |
$41,850 |
$41,850 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
350,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$5,692,673 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Oncology Impact Fund (cayman) Management L.p. |
10% Owner |
|
2021-09-08 |
4 |
AS |
$28.61 |
$579,723 |
I/I |
(20,236) |
5,901,796 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-09-08 |
4 |
AS |
$28.61 |
$346,413 |
I/I |
(12,092) |
3,591,881 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-09-08 |
4 |
AS |
$28.61 |
$346,413 |
I/I |
(12,092) |
3,591,881 |
|
- |
|
Oncology Impact Fund (cayman) Management L.p. |
10% Owner |
|
2021-09-07 |
4 |
AS |
$0.00 |
$0 |
I/I |
(31,340) |
5,922,032 |
|
- |
|
Oncology Impact Fund (cayman) Management L.p. |
10% Owner |
|
2021-09-07 |
4 |
AS |
$29.18 |
$1,488,063 |
I/I |
(50,996) |
5,953,372 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-09-07 |
4 |
AS |
$0.00 |
$0 |
I/I |
(31,340) |
3,603,793 |
|
- |
|
Mpm Bioventures 2018 Gp Llc |
10% Owner |
|
2021-09-07 |
4 |
AS |
$29.18 |
$889,231 |
I/I |
(30,474) |
3,635,313 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-09-07 |
4 |
AS |
$0.00 |
$0 |
I/I |
(31,340) |
3,603,793 |
|
- |
|
Mpm Asset Management Investors Bv2018 Llc |
10% Owner |
|
2021-09-07 |
4 |
AS |
$29.18 |
$889,231 |
I/I |
(30,474) |
3,635,313 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-09-02 |
4 |
AS |
$28.91 |
$334,796 |
D/D |
(11,568) |
105,437 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-09-01 |
4 |
AS |
$28.30 |
$245,722 |
D/D |
(8,684) |
117,005 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-08-31 |
4 |
AS |
$28.12 |
$115,095 |
D/D |
(4,093) |
125,689 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-08-30 |
4 |
AS |
$28.01 |
$65,039 |
D/D |
(2,322) |
129,782 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-08-27 |
4 |
AS |
$28.17 |
$232,346 |
D/D |
(8,248) |
132,104 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-08-25 |
4 |
AS |
$28.00 |
$24,109 |
D/D |
(861) |
140,352 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-08-24 |
4 |
AS |
$28.26 |
$6,359 |
D/D |
(225) |
141,213 |
|
- |
|
Detheux Michel |
Chief Executive Officer |
|
2021-08-23 |
4 |
AS |
$28.06 |
$210,422 |
D/D |
(7,499) |
141,438 |
|
- |
|
Call Matthew |
Chief Operating Officer |
|
2021-07-30 |
4 |
OE |
$2.95 |
$158,332 |
D/D |
53,672 |
53,672 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-06-08 |
4 |
AS |
$20.00 |
$158,540 |
D/D |
(7,927) |
0 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-06-08 |
4 |
OE |
$4.23 |
$33,531 |
D/D |
7,927 |
7,927 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-06-02 |
4 |
AS |
$20.00 |
$6,460 |
D/D |
(323) |
0 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-06-02 |
4 |
OE |
$4.23 |
$1,366 |
D/D |
323 |
323 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-06-01 |
4 |
AS |
$20.18 |
$153,443 |
D/D |
(7,604) |
0 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-06-01 |
4 |
OE |
$4.23 |
$32,165 |
D/D |
7,604 |
7,604 |
|
- |
|
Mcgrath Yvonne |
VP, Research and Development |
|
2021-05-24 |
4/A |
AS |
$21.92 |
$173,796 |
D/D |
(7,927) |
0 |
|
- |
|
229 Records found
|
|
Page 8 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|